

# Interprotein Corporation Product Pipeline Review 2016

*'Interprotein Corporation Product Pipeline Review - 2016', provides an overview of the Interprotein Corporation's pharmaceutical research and development focus*

PUNE, INDIA, April 14, 2016 /EINPresswire.com/ -- The report "[Interprotein Corporation - Product Pipeline Review - 2016](#)" provides comprehensive information on the therapeutics under development by Interprotein Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Access a Report Copy @ <https://www.wiseguyreports.com/reports/interprotein-corporation-product-pipeline-review-2016> .

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note\*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

## Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Interprotein Corporation
- The report provides overview of Interprotein Corporation including its business description, key

facts, and locations and subsidiaries

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Interprotein Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Interprotein Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Purchase a 1-User License Copy @

[https://www.wiseguyreports.com/checkout?currency=one\\_user-USD&report\\_id=393573](https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=393573) .

Reasons to buy

- Evaluate Interprotein Corporation's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Interprotein Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interprotein Corporation's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Major Point in Table of Content

Interprotein Corporation - Drug Profiles 16

IPC-003 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

Small Molecules to Inhibit VEGF for Solid Tumors 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

Small Molecule to Inhibit gp130 for Inflammation and Oncology 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Small Molecule to Inhibit IgE for Allergies 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Small Molecules to Inhibit RUNX1 for Acute Myeloid Leukemia 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Synthetic Peptide to Inhibit gp130 for Inflammation and Oncology 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Synthetic Peptides to Antagonize KIR for Oncology 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Synthetic Peptides to Antagonize NKG2A for Oncology 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Synthetic Peptides to Inhibit TIM-3 for Oncology 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Inquire for more information @ <https://www.wiseguyreports.com/enquiry/interprotein-corporation-product-pipeline-review-2016> .

Norah Trent

WiseGuy Research Consultants Pvt. Ltd.

16468459349

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/321380870>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

